Top Tweets for #IFINATAMAB

about 1 month ago

Losing the accelerated path for #ifinatamab deruxtecan (I-DXd) turns the B7-H3 race in small cell lung cancer into a confirmatory-trial race, one @Merck and Daiichi Sankyo no longer lead by default, since @US_FDA says the data so far won't support it and timing was $MRK's edge.

biotech_leads's tweet photo. Losing the accelerated path for #ifinatamab deruxtecan (I-DXd) turns the B7-H3 race in small cell lung cancer into a confirmatory-trial race, one @Merck and Daiichi Sankyo no longer lead by default, since @US_FDA says the data so far won't support it and timing was $MRK's edge. https://t.co/FU0joyKBb7

167

Pharma Jonpi . / 1.1 / . @pharma_jonpi

about 2 years ago

#ESMO24. #SMALL_CELL_LUNG_CÁNCER SEGUNDA LÍNEA . COMPARATIVA DE PFS PRESENTADAS : PFS CON #YL_201 DE ##MEDLINK : 6,2 MESES . PFS CON #IFINATAMAB #DERUXTECAN DE #MERCK : 5,5 MESES . PFS CON #GSK_764227 DE #GLAXO_SMITH : 5,9 MESES. https://t.co/bd0tO55Ye1 #amgen #roche #jazzpharma

pharma_jonpi's tweet photo. #ESMO24. #SMALL_CELL_LUNG_CÁNCER SEGUNDA LÍNEA . COMPARATIVA DE PFS PRESENTADAS : PFS CON #YL_201 DE ##MEDLINK : 6,2 MESES . PFS CON #IFINATAMAB #DERUXTECAN DE #MERCK : 5,5 MESES . PFS CON #GSK_764227 DE #GLAXO_SMITH : 5,9 MESES.

https://t.co/bd0tO55Ye1 #amgen #roche #jazzpharma https://t.co/MAY0KIgEIl

Pharma Jonpi . / 1.1 / . @pharma_jonpi

about 2 years ago

#Ifinatamab #Deruxtecan (#Daiichi_Sankyo #Merck) es la Estrella del #WCLC24 al Demostrar una Actividad Clínica Mejorada en Dosis Más Alta Para #SAMLL_CELL_LUNG_CANCER PRETRATADO: ORR del 54,8%, una PFS de 5,5 Meses, una OS de 11,8 Meses. #pharmamar #amgen https://t.co/bd0tO56w3z

pharma_jonpi's tweet photo. #Ifinatamab #Deruxtecan (#Daiichi_Sankyo #Merck) es la Estrella del #WCLC24 al Demostrar una Actividad Clínica Mejorada en Dosis Más Alta Para #SAMLL_CELL_LUNG_CANCER PRETRATADO: ORR del 54,8%, una PFS de 5,5 Meses, una OS de 11,8 Meses.
#pharmamar #amgen
https://t.co/bd0tO56w3z https://t.co/G7FypoNkCs

Pharma Jonpi . / 1.1 / . @pharma_jonpi

about 2 years ago

Comienza la FASE III #IDeate_Lung02 de #Ifinatamab #Deruxtecan Para #Small_Cell_Lung_Cancer RECIDIVANTE (Segunda Línea). Un ENSAYO GLOBAL Que Evalúa la Eficacia y Seguridad FRENTE a #Amrubicina, #Lurbinectedin o #Topotecan. https://t.co/svoUdSbMHm #pharmamar #jazzpharma @US_FDA

pharma_jonpi's tweet photo. Comienza la FASE III #IDeate_Lung02 de #Ifinatamab #Deruxtecan Para #Small_Cell_Lung_Cancer RECIDIVANTE (Segunda Línea). Un ENSAYO GLOBAL Que Evalúa la Eficacia y Seguridad FRENTE a #Amrubicina, #Lurbinectedin o #Topotecan.

https://t.co/svoUdSbMHm #pharmamar #jazzpharma @US_FDA https://t.co/myiDuPSzWj

Decera Clinical Education

@DeceraClinEdu

over 2 years ago

@triparnasen @NarjustFlorezMD @LealTiciana @AnaVManana @MomaVelez11 @CharuAggarwalMD @ChristianRolfo @BrunaPellini @drshieldsmd @NaglaAKarimMD @LuisPaz_Ares @LiveLung1 @lcrf_org 9/ #Ifinatamab #deruxtecan B7-H3–targeted ADC in #SCLC: ⚡️Phase I/II after ≥2 LoT = ORR 52.4% ⚡️Phase III IDeate-2: I-DXd vs SoC tx after ≥1 Plt-based regimen (NCT06203210) ⚡️Phase II IDeate: I-DXd after ≤3 prior LoT, including ≥1 prior Plt-based chemo (NCT05280470)

DeceraClinEdu's tweet photo. @triparnasen @NarjustFlorezMD @LealTiciana @AnaVManana @MomaVelez11 @CharuAggarwalMD @ChristianRolfo @BrunaPellini @drshieldsmd @NaglaAKarimMD @LuisPaz_Ares @LiveLung1 @lcrf_org 9/ #Ifinatamab #deruxtecan B7-H3–targeted ADC in #SCLC:
⚡️Phase I/II after ≥2 LoT = ORR 52.4%
⚡️Phase III IDeate-2: I-DXd vs SoC tx after ≥1 Plt-based regimen (NCT06203210)
⚡️Phase II IDeate: I-DXd after ≤3 prior LoT, including ≥1 prior Plt-based chemo (NCT05280470) https://t.co/pR2QNx0KWb

411

Decera Clinical Education

@DeceraClinEdu

over 2 years ago

@triparnasen @NarjustFlorezMD @LealTiciana @AnaVManana @MomaVelez11 @CharuAggarwalMD @ChristianRolfo @BrunaPellini @drshieldsmd @NaglaAKarimMD @LuisPaz_Ares @LiveLung1 @lcrf_org 8/📢There are no FDA-approved 3L options for ES-SCLC! 🗝️ Novel agents in development for the treatment of ES-SCLC include #Ifinatamab deruxtecan (IDX-d) and #Tarlatamab, with more on the horizon! 👏👏 @NarjustFlorezMD @triparnasen #Lungcancer #SCLC #MedEd #Xtorial

日本臨床腫瘍学会（JSMO）

@JSMO_official

over 2 years ago

ご紹介続きです！ #JSMO2024 Presidential Session 3 「新規抗体薬物複合体」 #乳癌 #固形がんの新規 #AntibodyDrugConjugate (ADC)の試験をご紹介します！ 2月23日（金） 15:00～17:20 Room 1（1号館2F「センチュリーホール」） by SNS-WG #DatoDXd #Sacituzumabgovitecan #ifinatamab deruxtecan

JSMO_official's tweet photo. ご紹介続きです！
#JSMO2024 Presidential Session 3
「新規抗体薬物複合体」
#乳癌 #固形がんの新規 #AntibodyDrugConjugate (ADC)の試験をご紹介します！
2月23日（金） 15:00～17:20
Room 1（1号館2F「センチュリーホール」）
by SNS-WG
#DatoDXd #Sacituzumabgovitecan #ifinatamab deruxtecan https://t.co/PF876acHHT

Rami Manochakian MD, FASCO

@RManochakian

about 3 years ago

🔥🚨@OncoAlert Hot off the press, presented @IASLC #WCLC23, by the amazing @MLJohnsonMD2, results of subgroup analysis of phase 1/2 study of #Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory #SCLC. ORR: 52% mDOR: 5.9 months mPFS: 5.6 months mOS: 12.2 months No new safety signals.

$RManochakian's tweet photo. 🔥🚨@OncoAlert Hot off the press, presented @IASLC #WCLC23, by the amazing @MLJohnsonMD2, results of subgroup analysis of phase 1/2 study of #Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory #SCLC. ORR: 52% mDOR: 5.9 months mPFS: 5.6 months mOS: 12.2 months No new safety signals.$

Top Tweets for #IFINATAMAB

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users